Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Event-driven biotech momentum: shares are up about 42% over 21 trading days, Corcept raised 2026 revenue guidance, plans to resubmit the relacorilant NDA in Cushing's syndrome, and recent clinical updates keep the catalyst calendar active.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Quarterly Weakness CORT's balance sheet and full-year profitability remain strong, but the latest quarter's loss, heavy stock-based compensation, and rich valuation raise execution risk. Valuation: The stock looks expensive unless CORT can consistently sustain its annual-level margins and cash generation.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Range top test ⢠Volatility risk Support Level: $86-$87 Resistance Level: $94.04 CORT has stayed in a constructive uptrend over the last month, with higher lows and a rebound from $86-$87, but a clean break above $94.04 is likely needed to unlock more upside.
Sentiment & News
Key News Insights: ⢠FDA catalyst ⢠Revenue growth ⢠Legal scrutiny Corcept's outlook looks increasingly tied to relacorilant FDA progress and revenue upside, but legal scrutiny and a recent insider sale temper the bullish setup.
AI Summary
CORT has evolved from a dependable orphan-drug cash generator into a catalyst-driven, higher-upside story where relacorilant's FDA outcome and oncology execution are now the main drivers of whether its strong balance sheet and margins can support a durable second growth leg.
Description
Corcept Therapeutics is a U.S.-based biopharmaceutical company that discovers, develops and commercializes drugs for severe metabolic, oncologic and neuropsychiatric conditions. It markets Korlym (mifepristone) for hyperglycemia secondary to endogenous Cushingâs syndrome in adults with type 2 diabetes or glucose intolerance who have not had successful surgery or are ineligible, and has clinical-stage programs including relacorilant for Cushingâs and combination studies with nab-paclitaxel in advanced ovarian tumors, alongside separate programs targeting prostate cancer, antipsychotic-induced weight gain and FKBP5-related diagnostics. Founded in 1998, the company is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 8 | Jun 15 | CORT | Corcept Therapeutics Incorporated | Event-driven biotech momentum: shares are up about 42% over 21 trading days, Corcept raised 2026 revenue guidance, plans to resubmit the relacorilant NDA in Cushing's syndrome, and recent clinical updates keep the catalyst calendar active. | Closed | +13.4% |